Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jul 30, 2012Eisai Plans to Submit Applications for Marketing Approval throughout the Americas
WOODCLIFF LAKE, NJ, and SAN DIEGO, CA, July 30, 2012 -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that Arena has transferred the BELVIQ® (lorcaserin hydrochloride)...
-
Jul 25, 2012
Eisai Inc. announced today that the results of the study, "Adjunctive Perampanel For Refractory Partial-Onset Seizures: Randomized Phase III...
-
Jul 9, 2012
Eisai Inc. today announced preliminary results from a recently completed phase III study of Halaven versus capecitabine (Xeloda®) in women with...
-
Jun 27, 2012-- First Prescription Weight-Loss Treatment Approved by FDA in 13 Years -- Eisai to Launch BELVIQ in U.S. Following DEA's Completion of Scheduling Review --
San Diego, CA, and Woodcliff Lake, NJ, June 27, 2012 - Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved...
-
Jun 22, 2012
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announces the immediate appointment of Shaji Procida to the position of...